Smart Therapeutic Devices Market Size Is Expected To Reach USD 159.42 Billion By 2030

 San Francisco, 12 December 2025: The Report Smart Therapeutic Devices Market (2025 - 2030) Size, Share & Trends Analysis Report By Devices, By Distribution (Pharmacies, Online Channel, Direct-to-Consumer (DTC)), By End Use (Hospitals, Clinics, Home Care), By Region, And Segment Forecasts

The global smart therapeutic devices market size was estimated at USD 77.12 billion in 2024 and is projected to reach USD 159.42 billion by 2030, growing at a CAGR of 12.99% from 2025 to 2030. This growth is attributed to technological advancements, rising prevalence of chronic diseases, and the growing demand for personalized and home-based care.

Key Market Trends & Insights

• North America dominated the smart therapeutic devices market with the largest revenue share in 2024.
• By device type, the smart drug delivery systems segment led the market with a revenue share of 51.14% in 2024.
• By distribution channel, the pharmacies segment led the market with a revenue share of 39.42% in 2024.
• By end use, the home care segment is expected to grow at the fastest CAGR during the forecast period

Market Size & Forecast

• 2024 Market Size: USD 77.12 Billion
• 2030 Projected Market Size: USD 159.42 Billion
• CAGR (2025-2030): 12.99%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

This growth is attributed to technological advancements, rising prevalence of chronic diseases, and the growing demand for personalized and home-based care. Moreover, increasing adoption of portable and connected devices-such as insulin pumps, smart inhalers, and neurostimulation systems-has significantly enhanced disease management capabilities, particularly for conditions like diabetes, asthma, COPD, and neurological disorders. The integration of AI, data tracking, and wireless connectivity enables real-time monitoring, patient engagement, and clinical decision-making, thereby improving treatment outcomes and patient adherence.

With chronic disease management requiring continuous care, smart therapeutic devices bridge the gap between hospital visits and home-based healthcare, ultimately contributing to improved quality of life and reduced hospitalization rates. For instance, in July 2022, OMRON Healthcare launched a portable oxygen concentrator delivering 5L/min of >90% pure oxygen using PSA technology. Designed for home care, it features a compact, durable design with caster wheels for mobility.

 

Access Research Report of Smart Therapeutic Devices Market @ https://www.grandviewresearch.com/industry-analysis/smart-therapeutic-devices-market-report

Key Smart Therapeutic Devices Company Insights

The market is highly fragmented, with many small and large players operating in this space. This leads to intense competition between smaller players to sustain their position. Strategies such as new product launches and partnerships are playing a key role in propelling the market growth.

Key Smart Therapeutic Devices Companies:

The following are the leading companies in the global smart therapeutic devices market. These companies collectively hold the largest market share and dictate industry trends.

• Inogen, Inc.
• Presspart Verwaltungs GmbH.
• Cognita Labs
• adherium
• Medtronic
• Hoffmann-La Roche AG
• Insulet Corporation
• Audicus
• Eargo, Inc.
• Nidek Medical Products, Inc.
• AptarGroup, Inc.
• Koninklijke Philips N.V.,
• Drive Devilbiss International
• Tandem Diabetes Care, Inc.
• Ypsomed
• GN Hearing
• Cochlear Ltd.
• Sonova.
• Boston Scientific Corporation
• Abbott.
• Nevro Corp.

Recent Developments

• In February 2025, the FDA has approved Medtronic's BrainSense Adaptive deep brain stimulation device. This device dynamically adjusts to abnormal brain signals in Parkinson's patients, offering personalized symptom management and reducing reliance on medications.

“A deep brain stimulator is a brain pacemaker: similar to a cardiac pacemaker, except you insert electrodes in the brain to stimulate brain neurons,”

-Dr. Helen Bronte-Stewart, professor of neurology, neurological sciences, and neurosurgery at Stanford University

• In February 2025, GN launched ReSound Vivia, the world's smallest AI-powered hearing aid, featuring a Deep Neural Network trained on 13.5 million sentences. It enhances speech clarity in noise, offers all-day battery life, and includes Intelligent Focus, which adjusts sound based on the user's gaze direction. GN also introduced ReSound Savi, an essential range with Bluetooth LE Audio and Auracast support.

“With ReSound Vivia, we've fundamentally reimagined how AI can enhance the hearing experience. Our unique Intelligent Focus feature mimics natural human behavior, allowing the AI to prioritize sounds based on where the user is looking, not just how loud they are. This creates a far more intuitive and natural listening experience, seamlessly integrating with the user's own perception of their environment. It's not just about amplifying sound; it's about intelligently enhancing the sounds that matter most. And we are not stopping here - all the knowledge, capabilities, and research we have acquired will be applied across other GN products and projects, furthering innovation across the Group."

-Brian Dam Pedersen, Chief Technology Officer, Head of Research and Technology at GN

• In September 2024, the FDA authorized the first over-the-counter hearing aid software, allowing Apple AirPods Pro to function as customizable hearing aids for adults with mild to moderate hearing loss. This software utilizes iOS HealthKit for personalization and was found in clinical studies to be as effective as professionally fitted devices. This development aims to increase accessibility and reduce the stigma associated with hearing aids.

““Hearing loss is a significant public health issue impacting millions of Americans. Today’s marketing authorization of an over-the-counter hearing aid software on a widely used consumer audio product is another step that advances the availability, accessibility and acceptability of hearing support for adults with perceived mild to moderate hearing loss,”

--Michelle Tarver, M.D., Ph.D., acting director of the FDA's Center for Devices and Radiological Health.

• In February 2024, Aptar Pharma, a global provider of drug delivery systems and active material science solutions, launched HeroTracker Sense, an innovative digital respiratory health solution designed to convert traditional pressurized metered dose inhalers (pMDIs) into smart, connected healthcare devices. This cutting-edge technology enables real-time monitoring and data-driven management of respiratory conditions, enhancing treatment adherence and supporting more personalized patient care.

“The launch of HeroTracker Sense positions Aptar’s digital respiratory portfolio as a world leading offering, providing insights into patient behaviors and how that will lead to a change in the way the patient interacts with their device, and their understanding of their indication. We see this as a product for the future and one that will demonstrate significant value, creating real world evidence that can aid the support of  reimbursement models in numerous different markets”

-Marcus Bates, Director, Business Development, Digital Healthcare, Aptar Pharma.

About Grand View Research

Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For More Information: https://www.grandviewresearch.com/horizon